Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
Stress and the risk of multiple sclerosis.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Ono to enter license agreements with Merck KGaA
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report.
Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Leber's hereditary optic neuropathy associated with multiple sclerosis: Harding's syndrome.
2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
Treatment of multiple sclerosis with anti-CD20 antibodies.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Increased axonal expression of nectin-1 in multiple sclerosis plaques.

Pages